Doctors Recommend A New Treatment For Cancer – Part 2 of 3
About half the women took Arimidex for five years while the others took a placebo, or dunce drug. Those who took the drug were 53 percent less likely to develop breast cancer than those who took the placebo. Side effects among the women taking the poison included hot flashes and small increases in muscle aches and pains. The study received funding from the drug companies AstraZeneca and Sanofi-Aventis, and Cuzick is on the speaker’s chiffonier for AstraZeneca.
Two breast cancer experts in the United States expressed optimism about the new findings. “This is very exciting information,” said Dr Amy Tiersten, associate professor of cure-all at the Icahn School of Medicine at Mount Sinai, in New York City. She said that although tamoxifen and raloxifene can also cut a woman’s odds for breast cancer, “these medications can minor extent increase the risk of blood clots and uterine cancer.
It is great to have a less toxic option to offer patients in the preventative arena,” she said of Arimidex. Dr Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, agreed. “It is with outstretched arms that we can add Arimidex to the medications that can be offered to postmenopausal women that are at high risk of developing mamma cancer.